From bedding to bedside: Genetically engineered mouse models of cancer inform concurrent clinical trials

Pigment Cell and Melanoma Research

Volumn 25, Issue 4, 2012, Pages 404-405

  Damsky, William E ^a   Bosenberg, Marcus ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; PROTEIN KINASE LKB1; SELUMETINIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GAIN OF FUNCTION MUTATION; GENE INACTIVATION; GENOTYPE; HUMAN; MELANOMA; MOUSE; NONHUMAN; NOTE; ONCOGENE; ONCOGENE K RAS; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENETIC ENGINEERING; HUMANS; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RAS PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84862681788     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01013.x     Document Type: Note

References (6)

1. Cairns, R.A., Harris, I.S., and Mak, T.W. (2011). Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95.
2. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N.Engl. J. Med. 364, 2507-2516.
3. Damsky, W.E., and Bosenberg, M. (2010). Mouse melanoma models and cell lines. Pigment Cell Melanoma Res., 23, 853-859.
4. Damsky, W.E., Curley, D.P., Santhanakrishnan, M. et al. (2011). β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741-754.
5. Pittet, M.J., and Weissleder, R. (2011). Intravital imaging. Cell 147, 983-991.
6. Wen, J., Fu, J., Zhang, W., and Guo, M. (2011). Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod. Pathol. 24, 932-943.